MedPath
HSA Approval

PHENEXPECT SYRUP

SIN09014P

PHENEXPECT SYRUP

PHENEXPECT SYRUP

November 28, 1996

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Therapeutic

Pharmacy Only

Formulation Information

SYRUP

**RECOMMENDED DOSAGE:** Adults:1 to 2 teaspoonfuls to be taken 3 or 4 times a day.Children:6 to 12 years : 1 teaspoonful 3 times a day. 2 to 6 years : ½ teaspoonful 3 times a day.Note:1 teaspoonful is equal to 5 ml.

ORAL

Medical Information

**INDICATIONS:** For productive cough; symptomatic relief of sneezing and rhinorrhoea.

**CONTRAINDICATIONS:** Ammonium salts are contraindicated in the presence of impaired hepatic or renal function. Patients with narrow angle glaucoma; prostatic hypertrophy. Diphenhydramine may exacerbate porphyria.

R05FB01

cough suppressants and mucolytics

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PT ACTAVIS INDONESIA

Active Ingredients

AMMONIUM CHLORIDE

135 mg/5 ml

Ammonium chloride

DIPHENHYDRAMINE HCl

12.5 mg/5 ml

Diphenhydramine

Documents

Package Inserts

Att 8 AAAM6807 Phenexpect Syp PI Prop Ann.pdf

Approved: January 19, 2021

Download
© Copyright 2025. All Rights Reserved by MedPath